e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

85.42 -1.08 (-1.25%)

Streaming Delayed Price Updated: 12:23 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call ↗

April 25, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

Expert Ratings For Ionis Pharmaceuticals ↗

April 01, 2022

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Via Benzinga

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks ↗

March 17, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗

February 01, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble ↗

January 31, 2022

Pfizer signed on to develop a high triglycerides treatment in November 2019.

Via Investor's Business Daily

Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol ↗

April 04, 2022

Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have

Via Benzinga

Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment ↗

March 28, 2022

Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.

Via Investor's Business Daily

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints ↗

March 28, 2022

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Via Benzinga

Why Cramer Likes Ferguson And Stanley Black & Decker ↗

March 25, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More ↗

March 11, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Why Are Ionis Pharmaceuticals Shares Tanking Today? ↗

January 31, 2022

Pfizer Inc (NYSE: PFE) and Ionis Pharmaceuticals Inc (NASDAQ: IONS)

Via Benzinga

Where Ionis Pharmaceuticals Stands With Analysts ↗

December 14, 2021

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed ...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More ↗

March 02, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For Feb. 25, 2022: GameStop, Tesla, AMD And More ↗

February 25, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For Feb. 23, 2022: Palantir, GameStop, Tesla, And More ↗

February 23, 2022

Benzinga’s Daily Brief On Trending Tickers highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...

Via Benzinga

Benzinga's Daily Brief On Trending Tickers For Feb. 22, 2022: Tesla, GameStop, Lexicon And More ↗

February 22, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock? ↗

February 01, 2022

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12...

Via Benzinga

Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot? ↗

January 31, 2022

Currently, analysts expect Moderna sales to drop off after 2022.

Via Investor's Business Daily

Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA ↗

January 31, 2022

Today's 5 Stock Ideas: Netflix (NFLX) - Shares up premarket. Citigroup upgraded the stock from Neutral to Buy and announced a $450 price target. Also, Co-CEO Reed Hastings...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 31, 2022

Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1...

Via Benzinga

Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder ↗

January 24, 2022

The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗

January 14, 2022

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...

Via Benzinga

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021 ↗

December 14, 2021

Upgrades According to Wells Fargo, the prior rating for Douglas Emmett Inc (NYSE:

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy